| Literature DB >> 31336703 |
Abstract
Polyethylene glycol (Entities:
Keywords: PEG-conjugates; nanocarriers; polyethylene glycol (PEG); stabilization; stealth character
Year: 2019 PMID: 31336703 PMCID: PMC6680653 DOI: 10.3390/pharmaceutics11070327
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1Nano particulate delivery designs discussed in this review.
The nanostructures presented in this review and their preparation methods.
| Nanoparticle System | Pathways for Their Synthesis | Biomedical Applications |
|---|---|---|
| PCL-PEG-Biotin [ |
Activation of Biotin. Addition of PEG bis amine. Polymerization with ε-caprolactone. | Targeted paclitaxel chemotherapy drug to MCF-7 and HeLa cells. |
| Magnetite-PEG-Folate [ |
Coprecipitation of the two salts FeCl3·6H2O and FeCl2·6H2O. Addition of oleic acid and oleylamine for stabilization. Addition of PEG. Addition of activated folic acid. | Targeted delivery of doxorubicin (DOX) to HeLa cells. |
| PLGA-PEG-Mannose [ |
PEGylation of mannose by Mono t-BOC-protected PEG bis amine. Removal of t-BOC group. Reaction with activated PLGA. | Delivery of amphotericin B to macrophages via enhanced macrophage targeting and mannose-mannose uptake. |
| PCL-PEG-SMLP [ |
Copolymerization of PEG and PCL. Activation of PCL-PEG-COOH with EDC and NHS. Reaction with SMLP. | Specific delivery of four different (DTX-PMs) to a (PSMA) positive prostate LNCaP cells. |
| Coumarin-PEG-Gold [ |
Reaction of monothioacetate-PEG-OH with Coumarin isocyanate. Reduction of monothioacetate-PEG-Coumarin to SH-PEG-Coumarin. Attachment to Gold nanoparticles. | Rapid internalization and intracellular tracking in MDA-MB-231 cells. |
| TAMRA-PEG-Gold [ |
Attachment of SH-PEG-COOH to gold nanoparticles. Activation of Au-PEG-COOH with EDC. Reaction with TAMRA. | Qualitative fluorescence imaging of the internalized AuNPs. |
| GO-PEG-CY7 [ |
Activation of graphene oxide with chloroacetic acid. Activation of –COOH groups on GO-CH2-COOH with EDC. Conjugation of six-arm branched amine PEG on GO. Addition of Cy7 infrared dye. | In vivo fluorescence imaging in xenograft tumor mouse models. |
| Ibuprofen/Chitosan-PEG [ |
Increasing the degree of deacetylation of chitosan. Protection of the amine of chitosan with SDS. Reaction of NaH activated PEG with chlorinated Chitosan/SDS complex. Removal of the SDS surfactant. Addition of Ibuprofen drug and using TPP solution to form nanomicelles. | Encapsulation of ibuprofen, a poor water soluble drug, and in vitro release in gastrointestinal and simulated biological fluids. |
| Aspirin/Curcumin/PLGA-mPEG [ |
Preparation of PLGA-mPEG copolymer. Adding a predetermined amount of SH-Aspirin and/or Curcumin. Nanoparticles formation using a modified single-emulsion solvent evaporation process. | Synergistic anticancer effects on ES-2 and SKOV3 human ovarian carcinoma cells in vitro, and activation of the mitochondrial apoptosis pathway. |
| Doxorubicin/MSN-Gelatin-PEG [ |
Addition of CTAB surfactant. Hydrolysis and polycondensation of TEOS and APTES. Calcination of CTAB surfactant. Mixing Doxorubicin with the MSNs. Capping with hyaluronic acid. Coating, crosslinking and activating Gelatin with EDC respectively. Conjugation of mPEG-amine to the Gelatin. | In vitro improved cellular uptake and astonishing killing effectiveness to CD44-positive MDA-MB-231 cells. |
| AuNP-PEG- |
Attaching SH-PEG-COOH on AuNps. Activation of –COOG group with EDC and NHS. Substitution of activated –COOH group with Tat peptide. | Enhanced cellular uptake by Hela cells in vitro, and effectiveness in k generation of more oxygen reactive species resulting in cell death upon X-ray irradiation. |
| PLL-PEG-PLL [ |
Reaction of Triphosgene with L-Leucine. Polymerization of L-LeuNCA using BAPEG as initiator. | Drug loading and in vitro drug release. |
Figure 2Chemical connectivity of PCL-PEG-Biotin nanoparticle design.
Figure 3Magnetite-PEG-Folate nanoparticle, explaining how Folic acid (FA)-PEG-monooleate can form interdigitated bilayers to transfer hydrophobic magnetite into aqueous media, resulting in a biocompatible nanoparticulate system.
Figure 4Chemical connectivity of PLGA-PEG-Mannose nanoparticle design.
Figure 5Chemical connectivity of PCL-PEG-SMLP nanoparticle design and nanoparticle design of those mentioned in Section 2.1, Section 2.3 and Section 2.4.
Figure 6Targeted AuNp-PEG-Tat nanoparticle and chemical connectivity design.
Figure 7Chemical connectivity of Coumarin-PEG-Au nanoparticle design.
Figure 8Targeted nanoparticle presented in Section 3.1 and Section 3.2 and chemical connectivity of TAMRA-PEG-Au nanoparticle design.
Figure 9Graphene oxide (GO)-PEG-Cy7 nanoparticle design (obtained with permission from [22]).
Figure 10PLL-PEG-PLL chemical structure and nanoparticle design (nanomicelles) for drug loading and delivery.
Figure 11Chemical connectivity of Ibuprofen/PEG-Chitosan nanoparticle design.
Figure 12Nanoparticle design of those presented in Section 4.1, Section 4.2 and Section 4.3, and chemical connectivity of Ridaforolimus/NH2-PEG-DSPE nanoparticle design.
Figure 13Doxorubicin/mesoporous silica nanoparticles (MSN)-Gelatin-PEG nanoparticulate design.
Figure 14Doxorubicin hydrochloride (DOX)/MCN-PEG nanoparticulate design.